Charles River Laboratories International, Inc. (NYSE:CRL) Receives $412.69 Consensus Target Price from Analysts

Charles River Laboratories International, Inc. (NYSE:CRL) has been given a consensus rating of “Buy” by the fifteen research firms that are covering the company, MarketBeat reports. Four analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $412.69.

Several brokerages recently weighed in on CRL. Citigroup dropped their price target on shares of Charles River Laboratories International from $425.00 to $400.00 and set a “neutral” rating on the stock in a research report on Thursday, November 4th. Morgan Stanley dropped their price target on shares of Charles River Laboratories International from $480.00 to $465.00 and set an “overweight” rating on the stock in a research report on Thursday, November 4th. Evercore ISI reaffirmed a “buy” rating on shares of Charles River Laboratories International in a research report on Thursday, October 14th. Deutsche Bank Aktiengesellschaft increased their price objective on shares of Charles River Laboratories International from $354.00 to $409.00 and gave the company a “buy” rating in a research note on Tuesday, November 16th. Finally, Robert W. Baird reiterated a “buy” rating on shares of Charles River Laboratories International in a research note on Monday, December 20th.

Shares of CRL stock traded up $2.35 on Friday, reaching $360.30. 7,694 shares of the company were exchanged, compared to its average volume of 602,227. The company has a market cap of $18.18 billion, a price-to-earnings ratio of 46.25, a PEG ratio of 2.08 and a beta of 1.17. The company has a 50-day moving average of $368.09 and a 200-day moving average of $398.05. The company has a debt-to-equity ratio of 1.19, a current ratio of 1.40 and a quick ratio of 1.22. Charles River Laboratories International has a one year low of $249.48 and a one year high of $460.21.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Tuesday, November 2nd. The medical research company reported $2.70 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.58 by $0.12. Charles River Laboratories International had a net margin of 11.58% and a return on equity of 23.14%. The business had revenue of $895.90 million for the quarter, compared to analysts’ expectations of $902.03 million. During the same quarter last year, the firm earned $2.33 EPS. The firm’s revenue for the quarter was up 20.5% compared to the same quarter last year. As a group, sell-side analysts predict that Charles River Laboratories International will post 10.25 EPS for the current year.

Several hedge funds have recently modified their holdings of the company. Fulton Bank N.A. boosted its holdings in Charles River Laboratories International by 19.4% in the 4th quarter. Fulton Bank N.A. now owns 1,753 shares of the medical research company’s stock worth $660,000 after buying an additional 285 shares during the period. UBS Asset Management Americas Inc. boosted its holdings in Charles River Laboratories International by 6.2% in the 3rd quarter. UBS Asset Management Americas Inc. now owns 139,005 shares of the medical research company’s stock worth $57,363,000 after buying an additional 8,172 shares during the period. Strategy Asset Managers LLC boosted its holdings in Charles River Laboratories International by 245.4% in the 3rd quarter. Strategy Asset Managers LLC now owns 3,067 shares of the medical research company’s stock worth $1,266,000 after buying an additional 2,179 shares during the period. Moors & Cabot Inc. bought a new position in Charles River Laboratories International in the 3rd quarter worth approximately $743,000. Finally, Hanlon Investment Management Inc. boosted its holdings in Charles River Laboratories International by 8.7% in the 3rd quarter. Hanlon Investment Management Inc. now owns 3,928 shares of the medical research company’s stock worth $1,621,000 after buying an additional 314 shares during the period. Institutional investors own 93.14% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc is an early-stage contract research company, which provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions. It operates through the following segments: Research Models & Services, Discovery & Safety Assessment and Manufacturing Support.

See Also: Limitations of analyzing profit margin

Analyst Recommendations for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.